- Home
- INKT vs ANTX Comparison
INKT vs ANTX Comparison
Compare INKT & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INKT
- ANTX
- Stock Information
- Founded
- INKT 2017
- ANTX 2017
- Country
- INKT United States
- ANTX United States
- Employees
- INKT N/A
- ANTX N/A
- Industry
- INKT Medicinal Chemicals and Botanical Products
- ANTX Biotechnology: Pharmaceutical Preparations
- Sector
- INKT Health Care
- ANTX Health Care
- Exchange
- INKT Nasdaq
- ANTX Nasdaq
- Market Cap
- INKT 36.7M
- ANTX 37.6M
- IPO Year
- INKT 2021
- ANTX 2022
- Fundamental
- Price
- INKT $10.10
- ANTX $1.13
- Analyst Decision
- INKT Strong Buy
- ANTX Hold
- Analyst Count
- INKT 2
- ANTX 5
- Target Price
- INKT $6.50
- ANTX $3.50
- AVG Volume (30 Days)
- INKT 70.0K
- ANTX 149.8K
- Earning Date
- INKT 03-20-2025
- ANTX 03-27-2025
- Dividend Yield
- INKT N/A
- ANTX N/A
- EPS Growth
- INKT N/A
- ANTX N/A
- EPS
- INKT N/A
- ANTX N/A
- Revenue
- INKT N/A
- ANTX N/A
- Revenue This Year
- INKT N/A
- ANTX N/A
- Revenue Next Year
- INKT N/A
- ANTX N/A
- P/E Ratio
- INKT N/A
- ANTX N/A
- Revenue Growth
- INKT N/A
- ANTX N/A
- 52 Week Low
- INKT $4.56
- ANTX $0.87
- 52 Week High
- INKT $19.00
- ANTX $3.88
- Technical
- Relative Strength Index (RSI)
- INKT 54.73
- ANTX 44.20
- Support Level
- INKT $8.97
- ANTX $1.09
- Resistance Level
- INKT $9.98
- ANTX $1.20
- Average True Range (ATR)
- INKT 1.44
- ANTX 0.05
- MACD
- INKT -0.07
- ANTX 0.01
- Stochastic Oscillator
- INKT 42.97
- ANTX 52.98
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T-cell therapies to treat cancer and other life-threatening illnesses.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.